A Data Management Perspective: How Are Device Trials Different from Drug Trials?
Many articles discussing the difference between drug and device trials come from a regulatory perspective on how clinical trials are designed and...
Traditional CROs fragment device development with costly hand-offs and learning curves. Veranex unites the essential disciplines for medical device & diagnostic development under one roof from sketch to evidence-generation to market launch.
All connected. All aligned. All accelerating your path to market—delivering breakthrough devices and diagnostics that improve patient lives sooner.
Breakthrough innovation requires more than great solutions; it demands deep expertise and insight. Veranex packages outcome-driven solutions with 25+ years of specialized knowledge across major medtech categories, delivering integrated capabilities that solve your most pressing challenges faster and with greater certainty.
Purpose-built solutions. Proven results. User & Patient-centered innovation.
Whether you're transforming patient care or disrupting entire therapeutic categories, innovation requires more than great science, it demands velocity. Veranex was founded to bridge the gap between visionary concepts and market reality, combining proven expertise with agile execution to accelerate the innovations that matter most.
We are the Innovation CRO.
Legacy of excellence. Proven execution. Patient impact accelerated.
What are the important items to be aware of? In this blog, we will look at these and other questions, with a focus on the data management/database build work within medical device studies for the US and EU.

Medical devices are an important part of healthcare. They run the spectrum from the common (e.g., bandages), to diagnostic tests and complex surgical interventions and drug delivery mechanisms. Before they can be put on the market, they need to be shown to be safe and effective. This is accomplished through testing based on regulatory requirements.
Depending on the ‘risk’ of the device and the geographic area (US, EU) of approval, the FDA has categorized this risk into 3 categories:
| Classification | Risk | FDA requirements | Examples |
| Class I | low | General controls | Bandages, hand-held surgical instruments |
| Class II | moderate | Special controls, such as Premarket Notification 510(k) | CT scanners, powered wheelchair, arthroscopic repair |
| Class III | high | Premarket Approval (PMA) | Implantable pacemaker, implanted prosthetics |
In addition to the regulatory requirements of the FDA, a relatively recent requirement from the EU, called the MDR Regulation (EU) 2017/745 on medical devices became effective in May 2021. This new regulation was developed to improve the safety, reliability and transparency of medical device information in the EU medical device market. This has created a need for additional post-marketing studies and safety reporting requirements for medical devices.
Together, the FDA and EU requirements present special challenges for clinical trial processes and gathering of necessary data for analyses to support the approval of medical devices.
A database-build directly influences the quality of the study data and is an important part of the medical device study. The regulatory informational needs from both the FDA and EU need to be included in the overall strategy for building a quality and effective database.
The term ‘database’ often refers to both the collected data as well as the database management system (DBMS) — or software that interacts with the end-users, applications, and data itself.
Types of data include:
What is a database build?
The set-up of a database plans for all data streams and may include strategies for skip logic, intelligent guided entry, and pop-ups to simplify the entry of data points following the ALCOA principles (Attributable, Legible, Contemporaneous, Original and Accurate) and to maintain the GCP principles for data reporting and data integrity. It must also be able to handle large amounts of data, found in many post-market surveillance device studies.
The ability to integrate the various sources of data, from the eCRF data to the electronic sources, into an effective clinical solution that is accessible and supports regulatory reporting requirements, can be a challenge.
Finding the right EDC system to meet the study needs and requirements at the right price point is needed for both the satisfaction of the sponsor as well as the data management team. Will the trial have decentralized monitoring? Are advanced analytics and visualizations needed? Working knowledge of the various EDC systems as well as the technology to support needed capabilities is important.
Device-Specific Information Challenges
Specific information on the devices is needed for reporting purposes.
As a CRO specializing in medical devices, we have supported database builds for Class I, II and III trials. The needs for Class I trials are the least of all trials, requiring only a study protocol and source document for the few PRO (patient-reported outcome) forms. A Class III trial (PMA) is the most extensive effort of the three with systems designed to capture secondary and tertiary endpoint information.
| Class 1 | Class 2 | Class 3 |
| Low Risk: Surgical Instruments, Bandages, etc. | Moderate Risk: Syringes, Sutures, etc | High Risk: Pacemakers, Shoulder rotator cuff, etc. |
|
|
|
Concentrating on the uniqueness of device trials, rather than the typical efforts that contribute to a database build would include:
These challenges are different from the processes and data needs of a clinical trial for a drug and are best met with the expertise of professionals working with device trials based on relevant regional experience. Veranex' clinical data management will transform your trial data into actionable insights, ensuring unparalleled accuracy, efficiency, and compliance that drive successful outcomes.
That expertise lives inside Veranex' end-to-end integrated services for medical device innovators at proficient in every stage and every discipline from research through manufacturing. Wherever you are in your medical device's commercialization pathway, we can help. Start the conversation today.
References:
1. Drozda JP Jr, Graham J, Muhlestein JB, Tcheng JE, Roach J, Forsyth T, Knight S, McKinnon A, May H, Wilson NA, Berlin JA, Simard EP. Multi-institutional distributed data networks for real-world evidence about medical devices: building unique device identifiers into longitudinal data (BUILD). JAMIA Open. 2022 May 25;5(2):ooac035. doi: 10.1093/jamiaopen/ooac035. PMID: 35663113; PMCID: PMC9154019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9154019/
Many articles discussing the difference between drug and device trials come from a regulatory perspective on how clinical trials are designed and...
2 min read
Clinical utility describes the usefulness of a medical product (device, diagnostic/prognostic, or therapeutic) for physicians and/or patients, and...
1 min read
No industry or device is immune from the risk of cyber attacks. And it’s especially important that medical devices including diagnostic...